Investor Presentaiton
II. Carragelose® significantly inhibit SARS-CoV-2
replication in tissue culture
New Data published on August 21st from independent group in Argentina/USA
SARS-CoV-2 virus replication inhibition
(Log10 TD50)
7.00
marino
med
6.00
5.00
4.00
3.00
2.00
1.00
0.00
Untreated 600 ug/ml 60 ug/ml 6 ug/ml 0.6 ug/ml Placebo (P2)
SARS-COV-2 viral titer after treatment
with iota carrageenan and P2
(3 replicates per treatment)
Composition
1.2 mg/mL iota-carrageenan, 5 mg/mL sodium
chloride, pH 6-7. Vero E6 were pre-treated
with dilutions of Iota-Carrageenan with sample P2
(placebo without iota-carrageenan) to get 600 μg/mL,
60 μg/mL, 6 μg/mL, and 0.6 μg/mL final iota-
carrageenan concentration for 2 h. After a 2 h pre-
treatment, cells were infected with SARS-CoV-2 and
incubated for 48h in the presence of the same dilutions
of iota-carrageenan. Supernatants were harvested and
virus yield determined by an end point dilution assay
(TCID50). Controls consisted of untreated infected cells
or infected cells treated with P2 (no iota-carrageenan).
Results were determined using the Reed and Muench
formula and expressed as log TCID 50/mL. Dotted line
shows the limit of detection (LOD). Testing of samples
was performed in triplicate.
CarrageloseⓇ reduces SARS-CoV-2 virus replication by more than 99,99% or 4,75logs
even when the product is diluted by a factor of 1:200
Source: https://www.biorxiv.org/content/10.1101/2020.08.19.225854v1
6View entire presentation